HLA antigens and toxic reactions to sodium aurothiopropanol sulphonate and D-penicillamine in patients with rheumatoid arthritis.
AUTOR(ES)
Perrier, P
RESUMO
One hundred and forty-one patients with rheumatoid arthritis treated with aurothiopropanol sulphonate or D-penicillamine, or both were examined for HLA antigens to investigate the genetic influence on the occurrence of different adverse reactions during therapy. All 13 patients possessing HLA-DR3 had toxic reactions. The relative risk for DR3 positives of developing skin eruptions or proteinuria was calculated to be 10.5 times and seven times respectively that of DR3 negatives. The incidence of DR7 antigen in 94 patients with toxic reactions was significantly decreased (11% compared with 28% in controls) suggesting a protective role for this antigen.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1001721Documentos Relacionados
- D-penicillamine withdrawal in rheumatoid arthritis.
- Hepatotoxicity associated with use of D-penicillamine in rheumatoid arthritis.
- Trial comparing D-penicillamine and gold in rheumatoid arthritis. Preliminary report.
- A biochemical comparison of alclofenac and D-penicillamine in rheumatoid arthritis.
- HLA system and side effects of gold salts and D-penicillamine treatment of rheumatoid arthritis.
